INR 1693.5
(2.36%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 908.84 Million INR | -34.48% |
2022 | 1.38 Billion INR | 30.86% |
2021 | 1.05 Billion INR | 9.73% |
2020 | 965.94 Million INR | -2.3% |
2019 | 988.69 Million INR | 56.52% |
2018 | 631.68 Million INR | 19.28% |
2017 | 529.58 Million INR | 21.43% |
2016 | 436.14 Million INR | -15.27% |
2015 | 514.76 Million INR | 13.37% |
2014 | 454.04 Million INR | 70.42% |
2013 | 266.43 Million INR | 16.76% |
2012 | 228.19 Million INR | 29.94% |
2011 | 175.61 Million INR | 65.73% |
2010 | 105.96 Million INR | 6.03% |
2009 | 99.93 Million INR | 24.77% |
2008 | 80.1 Million INR | -10.15% |
2007 | 89.14 Million INR | 163.53% |
2006 | 33.82 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 442.16 Million INR | -4.21% |
2024 Q1 | 251.81 Million INR | -1.98% |
2023 Q4 | 256.89 Million INR | -35.68% |
2023 FY | 908.84 Million INR | -34.48% |
2023 Q1 | 447.18 Million INR | 134.29% |
2023 Q3 | 399.38 Million INR | -4.9% |
2023 Q2 | 419.98 Million INR | -6.08% |
2022 Q3 | 411.53 Million INR | -5.37% |
2022 Q4 | 190.87 Million INR | -53.62% |
2022 FY | 1.38 Billion INR | 30.86% |
2022 Q1 | 333.96 Million INR | 151.65% |
2022 Q2 | 434.89 Million INR | 30.22% |
2021 Q4 | 132.71 Million INR | -59.19% |
2021 FY | 1.05 Billion INR | 9.73% |
2021 Q2 | 320.03 Million INR | 12.34% |
2021 Q3 | 325.21 Million INR | 1.62% |
2021 Q1 | 284.87 Million INR | 56.5% |
2020 Q4 | 182.02 Million INR | -28.07% |
2020 FY | 965.94 Million INR | -2.3% |
2020 Q3 | 253.06 Million INR | -6.0% |
2020 Q2 | 269.2 Million INR | 8.64% |
2020 Q1 | 247.79 Million INR | 612.01% |
2019 Q3 | 275.99 Million INR | -10.38% |
2019 Q4 | 34.8 Million INR | -87.39% |
2019 FY | 988.69 Million INR | 56.52% |
2019 Q1 | 248.37 Million INR | 547.24% |
2019 Q2 | 307.95 Million INR | 23.99% |
2018 Q3 | 211.17 Million INR | -19.1% |
2018 Q2 | 261.04 Million INR | 21.31% |
2018 Q1 | 215.19 Million INR | 0.0% |
2018 FY | 631.68 Million INR | 19.28% |
2018 Q4 | -55.53 Million INR | -126.3% |
2017 FY | 529.58 Million INR | 21.43% |
2016 FY | 436.14 Million INR | -15.27% |
2015 FY | 514.76 Million INR | 13.37% |
2014 FY | 454.04 Million INR | 70.42% |
2013 FY | 266.43 Million INR | 16.76% |
2012 Q4 | 70.51 Million INR | 16.97% |
2012 FY | 228.19 Million INR | 29.94% |
2012 Q1 | 47.75 Million INR | 0.0% |
2012 Q2 | 49.96 Million INR | 4.63% |
2012 Q3 | 60.28 Million INR | 20.66% |
2011 FY | 175.61 Million INR | 65.73% |
2010 FY | 105.96 Million INR | 6.03% |
2009 FY | 99.93 Million INR | 24.77% |
2008 FY | 80.1 Million INR | -10.15% |
2007 FY | 89.14 Million INR | 163.53% |
2006 FY | 33.82 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 94.273% |
Aurobindo Pharma Limited | 39.23 Billion INR | 97.684% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 92.193% |
Granules India Limited | 7.18 Billion INR | 87.346% |
Indoco Remedies Limited | 4.74 Billion INR | 80.862% |
Achyut Healthcare Limited | 1.6 Million INR | -56384.773% |
Ajanta Pharma Limited | 30.46 Billion INR | 97.017% |
Alkem Laboratories Limited | 32.83 Billion INR | 97.232% |
Alpa Laboratories Limited | 156.14 Million INR | -482.041% |
Brooks Laboratories Limited | 51.18 Million INR | -1675.772% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 65.05% |
Bajaj HealthCare Limited | 985.34 Million INR | 7.764% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 35.962% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.052% |
Eris Lifesciences Limited | 4.94 Billion INR | 81.613% |
FDC Limited | 5.34 Billion INR | 83.008% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.655% |
Gufic Biosciences Limited | 1.07 Billion INR | 15.669% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 57.215% |
Ipca Laboratories Limited | 13.91 Billion INR | 93.469% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -17.511% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1869.061% |
Lasa Supergenerics Limited | 291.17 Million INR | -212.13% |
Laurus Labs Limited | 3.01 Billion INR | 69.814% |
Lupin Limited | 95.67 Billion INR | 99.05% |
Mankind Pharma Limited | 23.15 Billion INR | 96.075% |
Medicamen Biotech Limited | 335.16 Million INR | -171.16% |
Medico Remedies Limited | 161.84 Million INR | -461.553% |
Megasoft Limited | 49.52 Million INR | -1735.002% |
NATCO Pharma Limited | 10.05 Billion INR | 90.964% |
Piramal Pharma Limited | 19.91 Billion INR | 95.436% |
RPG Life Sciences Limited | 1.63 Billion INR | 44.43% |
Sigachi Industries Limited | 579.88 Million INR | -56.727% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.411% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 35.212% |
Syncom Formulations (India) Limited | 942.39 Million INR | 3.561% |
Unichem Laboratories Limited | 6.72 Billion INR | 86.487% |
Wanbury Limited | 1.16 Billion INR | 21.714% |
Windlas Biotech Limited | 1 Billion INR | 9.704% |
ZIM Laboratories Limited | 1.01 Billion INR | 10.287% |
Zydus Lifesciences Limited | 43.17 Billion INR | 97.895% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 70.462% |
Divi's Laboratories Limited | 14.17 Billion INR | 93.586% |
Procter & Gamble Health Limited | 2.99 Billion INR | 69.659% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 17.302% |
Bal Pharma Limited | 389.89 Million INR | -133.102% |
Strides Pharma Science Limited | 9.16 Billion INR | 90.081% |
Venus Remedies Limited | 1.91 Billion INR | 52.573% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 70.438% |
Nectar Lifesciences Limited | 625.55 Million INR | -45.287% |
Shilpa Medicare Limited | 2.18 Billion INR | 58.321% |
Aarti Drugs Limited | 1.16 Billion INR | 22.154% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 17.288% |
Suven Life Sciences Limited | 109.75 Million INR | -728.1% |
Ind-Swift Limited | 946.56 Million INR | 3.986% |
Valiant Laboratories Limited | 36.28 Million INR | -2404.45% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 89.202% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 80.155% |
Themis Medicare Limited | 782.85 Million INR | -16.093% |
Hikal Limited | 2.48 Billion INR | 63.447% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 95.757% |
Sequent Scientific Limited | 2.9 Billion INR | 68.68% |
Novartis India Limited | 470.1 Million INR | -93.329% |
Wockhardt Limited | 6.4 Billion INR | 85.799% |
Jubilant Pharmova Limited | 14.45 Billion INR | 93.712% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -5506.767% |
Neuland Laboratories Limited | 2.92 Billion INR | 68.979% |
Morepen Laboratories Limited | 1.98 Billion INR | 54.271% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -120.364% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | -34.415% |